Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company specializing in treatments for obesity and type 2 diabetes (T2D), has announced it will release its fourth quarter and full year 2024 financial results on March 3, 2025, at 4:30 p.m. ET. The company will also provide business updates during the event.
A live webcast of the conference call will be available in the 'Events' section of Fractyl's investor relations website, with a replay option available after the event.
Fractyl Health (Nasdaq: GUTS), un'azienda di terapie metaboliche specializzata in trattamenti per l'obesità e il diabete di tipo 2 (T2D), ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 il 3 marzo 2025, alle 16:30 ET. L'azienda fornirà anche aggiornamenti aziendali durante l'evento.
Una diretta streaming della conferenza sarà disponibile nella sezione 'Eventi' del sito web delle relazioni con gli investitori di Fractyl, con un'opzione di replay disponibile dopo l'evento.
Fractyl Health (Nasdaq: GUTS), una empresa de terapias metabólicas especializada en tratamientos para la obesidad y la diabetes tipo 2 (T2D), ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el 3 de marzo de 2025, a las 4:30 p.m. ET. La empresa también proporcionará actualizaciones comerciales durante el evento.
Una transmisión en vivo de la conferencia estará disponible en la sección 'Eventos' del sitio web de relaciones con inversores de Fractyl, con una opción de repetición disponible después del evento.
Fractyl Health (Nasdaq: GUTS)는 비만 및 제2형 당뇨병 (T2D) 치료를 전문으로 하는 대사 치료 회사로, 2024년 4분기 및 연간 재무 결과를 2025년 3월 3일 오후 4시 30분 ET에 발표할 것이라고 발표했습니다. 회사는 또한 행사 중 비즈니스 업데이트를 제공할 예정입니다.
회의 전화의 라이브 웹캐스트는 Fractyl의 투자자 관계 웹사이트의 '이벤트' 섹션에서 제공되며, 행사 후 재생 옵션이 제공됩니다.
Fractyl Health (Nasdaq: GUTS), une entreprise de thérapies métaboliques spécialisée dans les traitements de l'obésité et du diabète de type 2 (T2D), a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 le 3 mars 2025 à 16h30 ET. L'entreprise fournira également des mises à jour commerciales lors de l'événement.
Une diffusion en direct de la conférence sera disponible dans la section 'Événements' du site web des relations avec les investisseurs de Fractyl, avec une option de rediffusion disponible après l'événement.
Fractyl Health (Nasdaq: GUTS), ein Unternehmen für metabolische Therapien, das sich auf Behandlungen von Fettleibigkeit und Typ-2-Diabetes (T2D) spezialisiert hat, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am 3. März 2025 um 16:30 Uhr ET veröffentlichen wird. Das Unternehmen wird während der Veranstaltung auch Geschäftsupdates bereitstellen.
Ein Live-Stream des Konferenzgesprächs wird im Bereich 'Veranstaltungen' auf der Investor Relations-Website von Fractyl verfügbar sein, mit einer Wiederholungsoption, die nach der Veranstaltung verfügbar ist.
- None.
- None.
BURLINGTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering pattern breaking approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the fourth quarter and full year 2024 and provide business updates on Monday, March 3, 2025, at 4:30 p.m. ET.
A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website at https://ir.fractyl.com/. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.
Contacts
Media Contact
Jessica Cotrone, Head of Corporate Communications
jcotrone@fractyl.com. 978.760.5622
Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
FAQ
When will Fractyl Health (GUTS) release Q4 and full year 2024 earnings?
How can investors access Fractyl Health's (GUTS) Q4 2024 earnings call?
What therapeutic areas does Fractyl Health (GUTS) focus on?
Will Fractyl Health (GUTS) provide business updates during their March 2025 earnings call?
